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Abstract
At least 10% of ovarian tumors are hereditary and associated with highly penetrant, autosomal, dominant genetic predisposition. Three
clinical manifestations of hereditary ovarian cancer have been identified: site-specific ovarian cancer, hereditary breast and/or ovarian cancer
(HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) syndromes. BRCA germline mutations account for more than 90% of all
hereditary epithelial ovarian tumors whereas most of the remaining 10% are caused by MLH1 and MSH2 mutations, which are susceptibility
genes of HNPCC. Genetic testing is available for each of the three hereditary syndromes above mentioned. The recommendations for OC
surveillance in high-risk women having a strong family history or BRCA mutation carriers include transvaginal pelvic ultrasound with color
Doppler and serum CA125 every 6 months. Bilateral salpingo-oophorectomy appears to be effective to reduce the risk of ovarian cancer
in BRCA mutation carriers. Hysterosalpingo-oophorectomy should be considered in HNPCC women who undergo surgery for colorectal
carcinoma.
© 2008 Elsevier Ireland Ltd. All rights reserved.
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In families with OC history, members affected by othereywords: Hereditary ovarian cancer; BRCA; HNPCC; Genetic testing; Pr
. Introduction
In the Western Countries, ovarian cancer (OC) is the lead-
ng cause of death from gynecological malignancy and is the
ourth cancer-related cause of death among women with an
stimated worldwide prevalence of 192,000 per year [1].
Due to absence of early symptoms and to the inadequacy
f available screening methods, OC are often diagnosed at an
dvanced stage resulting in a low survival rate.
Although no particular environmental risk factors have
een associated with ovarian carcinogenesis, the sex hor-
ones exposure and patient’s reproductive history are
articularly important. In the general population, the birth
f one live child reduces the risk of OC; after their first
regnancy women have a risk 45% lower as compared to nul-
iparous subjects. Every further pregnancy reduces the risk
y another 15% [2]. Differently from what happens with spo-
adic cancer, the risk of OC in BRCA1 mutation carriers has
een found to grow significantly with the number of born
hildren; after the fifth child, subsequent pregnancies have a
rotective effect [3]. Moreover, the risk of OC decreases as
he age at the last pregnancy increases and each 5 years inter-
al is associated with a risk reduction of 18%. Women who
ave all their children after the age of 30 as well as nulliparous
omen, belong to the lowest risk group. A case–control study
as reported that late pregnancies are protective against OC,
ut this has been proved only for patients with a family history
f OC [4].
Among the general population, women who have breast
ed at least one child present a reduced risk of developing
C but no data are available in women with an inherited
redisposition.
Beside the hormonal exposure, the only relevant risk factor
s a family history of OC; in fact, the risk of developing the
isease rises from 1.6% in the general population to 4% in
omen with a first-degree relative with OC and to 7% when
wo relatives are affected [5,6].
In women with strong familiarity, OC is generally diag-
osed at an earlier age as compared with the age of those who
evelop the disease without a family history.
Moreover in families with a high aggregation of cases
iagnosed with OC, the risk is related to the first-degree rela-
n
r
atic surgery
ive’s age at diagnosis. It has been established that the relative
isk of OC before the age of 55 is 5.2 and it decreases to 3.4
fter 55 years [7].
Anyway a first-degree relationship with an OC patient is
tself the major risk factor, while the age at which a relative
s diagnosed with cancer seems to have a minor effect with
egard to the OC risk.
The purpose of the present review is to give the primary
are clinician a useful tool to recognize and manage hered-
tary ovarian cancers due to mutations in either the BRCA
r the MMR genes. The paper is based on current literature
nd on our field experience with oncogenetic counseling for
ereditary breast/ovarian cancer and for Lynch II syndrome.
iven the huge extension of the subject we decided to pro-
ide a state of the art review and to avoid offering our critical
oint of view.
. Hereditary ovarian cancer syndromes
Up to 5–10% of all OCs are hereditary and associated with
dominant autosomic genetic predisposition at high pene-
rance. The detection of alterations in susceptibility genes is
t the basis of genetic counseling, that allows to individu-
te germline mutation carriers among subjects at high risk of
umor [8–10].
Although serous OC is the most common histological
ype, other specific subtypes can be found according to the
yndrome presenting the risk of an ovarian tumor [11].
OC seems to be the result of a multistep process due to the
ccumulation of genetic alterations, which, in women with
amiliarity for ovarian tumors, could be inherited. Beyond
utations in high penetrance major susceptibility genes,
ther low risk alleles or polymorphisms in different loci take
art in the ovarian carcinogenesis and the complexity of the
ntire process is to date far to be completely understood
12,13].eoplasms, like breast and colon cancer, can have a greater
isk of developing OC too. A strong family history of OC
nd correlated tumors could suggest three main syndromes:
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Table 1
Clinical manifestation of hereditary ovarian cancer
Susceptibility genes
Hereditary ovarian cancer syndrome
(HOC or site-specific ovarian
cancer)
BRCA1, BRCA2
Hereditary breast and ovarian cancer
syndrome (HBOC)
BRCA1, BRCA2
Hereditary non-polyposis colorectal
cancer syndrome (HNPCC or Lynch
II syndrome)
MMR genes (hMLH1,
hMSH2)
Other hereditary ovarian syndromes (<2%)
Gorlin Patch
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ePeutz-Jeghers syndrome STK11
Osteochondromatosis (Ollier’s
syndrome)
EXTs
ite-specific OC (hereditary ovarian cancer, HOC), hered-
tary breast and ovarian cancer (HBOC) and hereditary
on-polyposis colorectal cancer (HNPCC or Lynch II syn-
rome) which is characterized by colorectal cancer and an
ncreased risk of endometrial, ovarian, gastric, pancreatic and
iliary tract cancers [14,15].
The main contribution comes from breast cancer (BRCA)
enes mutations, which are susceptibility genes of the first
wo syndromes; 90% of hereditary OCs are linked to such
utations, while the remaining proportion is caused by
LH1 and MSH2 mutations, which are susceptibility genes
f the Lynch II syndrome [16–19].
There is also another group of minor familial syndromes
redisposing to OC, accounting for less than 1% of the
otal, such as the Gorlin’s syndrome, osteochondromato-
is or Ollier’s syndrome and the Peutz-Jeghers syndrome
15,20–22] (Table 1).
.1. Site-speciﬁc ovarian cancer
This syndrome is generally recognized in families in
hich two or more first- or first- and second-degree relatives
re affected by epithelial-type OC (Fig. 1). The lifetime risk
or OC in such family members is of about 5%, three-fold
igher than in the general population (1.6%) [5].
ig. 1. A pedigree of a real family with hereditary ovarian cancer syndrome
HOC). OC: ovarian cancer.
g
2
t
c
2
a
e
y
c
a
h
[
d
fi
(
uig. 2. A pedigree of a real family with hereditary breast and ovarian cancer
yndrome (HBOC). BC: breast Cancer; OC: ovarian Cancer.
It has been hypothesized that this disease could repre-
ent a variant of HBOC instead of a specific syndrome. A
ecent report confirms the former hypothesis and, since no
usceptibility gene has been identified specifically for OC,
his syndrome is still considered as a particular form of HBOC
ith a prevalence of OC [23].
.2. Hereditary breast and ovarian cancer
This syndrome is identified in families whose pedigree
resents members with both breast and OC (Fig. 2). OC can
e associated with many other cancers, but among these the
ost common is breast cancer. HBOC is characterized by
arly-onset breast cancer, OC at any age, bilateral breast can-
er, breast and ovarian cancer in the same individual or male
reast cancer [24–27].
Genetic predisposition to both breast cancer and OC may
e maternally and paternally inherited. The aggregation of
everal cases of breast and ovarian cancer and the early onset
f these malignancies have suggested a genetic predisposition
n these families. The two susceptibility genes associated with
pithelial-type OC are BRCA1 and BRCA2. Both of these
enes are autosomal dominant with high penetrance [28,29].
.2.1. The genetics of susceptibility: BRCA genes
The BRCA1 gene (OMIM 113705) was the first of the
wo oncosuppressor genes isolated in 1994 and mapped on
hromosome 17q21 [28]; it consists of 24 exons, of which
2 codify for a phosphoprotein of 1863 amino acids with
molecular weight of 220 kDa. Exon 11 of the gene is
xtremely large and codifies for 60% of the protein.
The BRCA2 gene (OMIM 600185), discovered about 1
ear later, is larger and sited in chromosome 13q12–13; it
onsists of 27 exons, of which 26 codify for a protein of 3418
mino acids. Both of these genes present a high structural
omology while they are different from other known genes
28–30] (Fig. 3).
In the N-terminal region of BRCA1 gene a ring ﬁnger
omain, typical of transcription factors, has been identi-
ed. BRCA1 N-terminal region colocalize with BARD 1
BRCA1-associated ring domain protein 1) and shows an
biquitin-ligase activity.
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eig. 3. BRCA1 and BRCA2 genes. Gray boxes indicate the exons with the
ith ovarian cancer risk are shown. Moreover, the figure indicates BRCA re
In the C-terminal region of the gene a BRCT domain
BRCA1 C-terminal) with some structural homologies with
53 and p21 and other cell cycle checkpoints proteins, has
een sequenced.
Moreover, BRCA1 plays a role in the cromatine remod-
ling process and interact with Rb and two other proteins of
he Histone Deacetylase Complex. Furthermore BRCA1 has
een found to colocalize with the CBP (CREB Binding Pro-
ein) region of RNA polimerase, and with Rad51, a protein
nvolved in the DNA repair mechanism [31–33].
The BRCA proteins have a nuclear localization, they are
xpressed in various tissues and play an important role in the
NA repair mechanisms. These proteins are also involved in
he control of the cell cycle checkpoints, in protein ubiqui-
inization and chromatin remodeling [34].
.2.2. BRCA genes mutations and OC
Mutations in the BRCA genes have been extensively
escribed in families affected by breast and/or OC. A mutated
RCA1 has been found in up to 75% of families with hered-
tary OC [11].
BRCA1/2 mutations include small deletions, insertions, or
untiform mutations leading to the formation of stop codons
ith a resulting nonfunctional truncated proteins. There are
o hot spots, so that the mutations are distributed throughout
he whole gene.
BRCA germline rearrangements have been described in
igh-risk breast/ovarian cancer families [12,35–37]. With
egard to this subject, Mazoyer summarized available data
nd reported 29 different BRCA1 germline rearrangements
nd only 3 for BRCA2, probably due to the differences exist-
ng between the two genes [38].
The cumulative lifetime risk of epithelial OC associated
ith mutations of the BRCA genes ranges from 40 to 50% for
RCA1 and from 20 to 30% for BRCA2. It has been calculatedhat these two genes together cause from 3 to 12% of all OCs
25,39].
An international database, known as the Breast Can-
er Information Core Database (BIC; http://www.research.
o
i
B
0mber provided below each box. Location of founder mutations associated
ore frequently involved in each gene.
hgri.nih.gov/bic), collects all the known gene vari-
nts observed in the two genes and their respective
requencies.
Recent studies on these mutations have highlighted the
ssociation between the site of the mutation and the risk
f OC. In fact, they have found mutations located between
ucleotides 2401 and 4190 of the gene BRCA1 increasing the
isk of OC, while they apparently reduce the risk of breast
ancer [40] (Fig. 3).
BRCA2 mutations are responsible for 35% of hereditary
reast cancer but confer a minor risk (10–20%) of developing
C [41].
Both genes are also involved in the development of male
reast cancer (6%) [42].
Reports state that there is a slight increase also, from 6 to
4%, in the risk of developing other types of cancer of the
olon, prostate and pancreas [43].
It has been reported that in the gene BRCA2, mutations
nvolving the portion 4075–6503 of exon 11, are associated
ith an increase in the risk of OC. This region has there-
ore been defined as the “Ovarian Cancer Cluster Region”
OCCR) [44–46].
There are no homozygosis mutations in the gene BRCA1,
hereas in BRCA2 such mutations lead to rare diseases, such
s Fanconi’s anemia and Wilms’ tumor [47]. This evidence
onfirms that, in spite of the considerable homology of the
wo genes, there are functional differences in their transduc-
ion products.
.2.3. BRCA founder mutations
The discovery that specific mutations in both genes could
e identified within specific populations and ethnic groups
as led to conduct population studies, resulting in the identi-
cation of “founder” mutations [48]. The most representative
xamples are those found in the genes BRCA1 and BRCA2
f Ashkenazi Jews. Three founder mutations have been
dentified to date in this population, BRCA1-185delAG,
RCA1-5382insC and BRCA2-6174delT, respectively in 1%,
.13% and 1.5% [41,49–58]; the risk of OC in carriers of this
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Table 2
Founder mutations of BRCA genes in various populations
BRCA1 BRCA2
Europe
1675delA (Norway) 999del5
(Ice-
land)
1135insA (Norway)
ins6KbEx13 (UK)
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gSA/Israel (Ashkenazi Jewish) 185delAG 6174delT
5382insC
hree founder mutations is respectively of 14%, 33% and 20%
49,57].
Two founder mutations have also been identified fre-
uently in cases of OC in the Norwegian population,
RCA1-1675delA in 2.1% and BRCA1-1135insA in 0.8%
59].
Another founder mutation identified is BRCA2-999del5 in
–7.9% cases of OC in Icelanders [60,61].
Finally, a recent study involving 283 cases of OC in the
K and in the USA seems to confirm the hypothesis that
he mutation ins6KbEx13 of the gene BRCA1 is a British
ounder mutation, since it has been found only in women of
ritish origin; in the UK this gene has been identified in 6%
f inherited OC cases [40] (Table 2).
Moreover, a “founder effect” has been shown for some of
he identified BRCA1 germline rearrangements recurring in
uropean populations [38].
.3. Ovarian cancer in the Lynch II syndrome
Several other tumors beside colon cancer may occur in
amilies affected by the Lynch II syndrome [17,18].
In such families ovarian, endometrial, uro-genital, pancre-
tic and biliary tract cancers, are not infrequently diagnosed
Fig. 4).
OC could occur three times more in a woman with a Lynch
I syndrome compared to the general population, but this risk
epends on the frequency of the disease among her first and
econd-degree relatives [62].
The syndrome involves genes related in the multi-
tep mechanisms of DNA repair, known as the mismatch
epair system (MMR genes) [63]. For women with
ig. 4. A pedigree of a real family with hereditary non-polyposis colorec-
al cancer (HNPCC). OC: ovarian cancer; CRC: colorectal cancer; End:
ndometrial cancer.
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MR genes mutations OC risk has been estimated to
e 9–12% [64].
Until now, very few studies have analyzed cases of OC
n HNPCC families; the disease presents with an early onset
ompared to sporadic OC even if it is not usually observed
efore the age of 45 [65].
Watson and the other members of the International Collab-
rative Group on HNPCC have established that most OCs in
NPCC family members are malignant epithelial cases, well
r moderately differentiated, FIGO stage I or II at diagnosis.
ynchronous endometrial cancer was reported in 21.5% of
ases. The more favorable clinical features of these cancers
ompared to sporadic cases may permit curative surgery [66].
.3.1. The genetics of susceptibility: MMR genes
Among HNPCC families, germline mutations in hMSH2
nd hMLH1 genes are found in over 70% of the mutation
arriers. Mutations in hPMS1, hPMS2 and hMSH6 are less
ommon, but also at high penetrance [67–69]. All these genes
re involved in the most important DNA repair mechanisms
nd are responsible for the repair of the nucleotide mismatch
uring DNA replication [70].
The MMR genes are located in five different chromosomes
nd codify for proteins that, as heterodimers, recognize and
epair DNA mismatches. The complex made up of the pro-
ein MSH2 with MSH6 or MSH3 recognizes and binds the
ismatch during S or G2 phases of cell cycle. MLH1 with
MS1 or PMS2 are involved in the fully resynthesis of the
NA strand [71].
An inactivating germline mutation of MSH2 blocks the
ormation of heterodimers which recognize damaged DNA,
hile MSH6 and MSH3 proteins have overlapping functions,
o that an alteration in one of these genes does not impede
he normal function of the DNA MMR system [72]. The
lteration of this pathway brings about an increased rate of
utations at the DNA microsatellites of growth-regulating
enes [73].
.3.2. MMR genes mutations and OC
MSH2 gene mutations appear to account for most Lynch
yndrome diagnosis and confer to women a 12% risk of devel-
ping an ovarian tumor during their life [74]. Several studies
ave attempted to discover possible haplotypes of these genes
hich, rather than mutations, might contribute to susceptibil-
ty to OC [75]. In fact, several common polymorphisms in the
MR genes may be associated with a variable cancer risk.
n a study of 1531 cases of OC and 2570 controls, Song et
l. have demonstrated that a specific single nucleotide poly-
orphism (SNP) of the gene PMS2 determine an increased
isk of OC, while two SNPs of MSH6 and MSH3 genes seem
o have a recessive protective effect, even though the com-
arisons of genotype frequencies for these variants were not
ignificant [76].
Whereas BRCA mutations have been identified mainly
n serous OCs, MMR genes mutations have been found
n various OC histotypes [11]. Furthermore, some cases
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Table 3
Lifetime risk estimate of developing ovarian cancer
General population BRCA1 BRCA2 MSH2
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f serous, undifferentiated OC present mutations in the
P53 gene, while endometrioid types have shown 90%
verexpression of BCL2 and microsatellite instability
MSI) and mucinous types present 40–50% of ki-RAS
utations [77].
Guidelines for HNPCC families’ identification have been
eferred to as the Amsterdam Criteria [78]. In individuals
hat meet these criteria, genetic testing is performed using
atients’ blood samples by a direct sequencing of suscepti-
ility genes, MLH1 and MSH2.
If the family history satisfies less stringent criteria such as
he Bethesda Criteria, it could be carried on a pre-screening
nalysis regarding microsatellite instability and immunohis-
ochemistry (IHC) [79,80]. These analyses require tumor
issue obtained from the youngest family member, without
erforming DNA mutational analysis. IHC is able to evaluate
he presence or not of the proteins MLH1, MSH2, MSH6 and
MS2 by means of specific antibodies but not to predict lack
f function due to the formation of truncated proteins [81].
he absence of one of the protein indicates which MMR genes
s most suitable for mutational analysis. Unfortunately, in the
ase of missense mutations, IHC does not permit molecular
iagnosis; even though the protein may be not functional,
ts presence could be detected. For this reason, IHC should
e used together with MSI analysis as a pre-screening test
79]. The microsatellite markers set used in HNPCC fam-
lies are the same used for sporadic tumors, which show
nstability in 10–15% of the cases compared to 85–92% in
amilial tumors [82,83]. Tumors are defined as having high
SI (H-MSI) when at least 30% of the markers are posi-
ive and as low (L-MSI) when positivity is less than 30%.
f none of the markers proves to be positive, the tumor is
efined as having stable MSI [84]. This method presents a
ensitivity of 93% in MMR genes mutation carriers, but with
egard to IHC, offers no indication as to which gene might be
ltered.
.4. Other hereditary syndromes predisposing to
varian cancer
An increased risk of ovarian cancer is associated with
everal hereditary syndromes, such as Gorlin’s syndrome,
he Peutz-Jeghers syndrome, osteochondromatosis or Ollier’s
yndrome.
These syndromes are linked to specific susceptibility
enes whose mutations may contribute to a particular OC
istotype.
Both the Peutz-Jeghers and Ollier’s syndrome may deter-
ine granulosa cell tumors in affected family members;
hey involve the STK11 gene and the EXTs genes, respec-
ively. Gorlin’s syndrome may cause basal cell carcinomas,
dontogenic cheratocysts and nevus diseases in Patch gene
utations carriers; it may also cause ovarian fibrosarcomas.
or members of families affected by these syndromes, the
isk of developing an ovarian tumor during their life is less
han 2% [11,20–22].
o
s
b
l.6 28-44 27 12
he risk is calculated between general population and carriers of BRCA1,
RCA2 and MSH2 mutations (%).
. Lifetime risk for familial ovarian cancer
The lifetime risk of members of families with genetic pre-
isposition depends on the susceptibility genes mutations;
RCA1 mutations seem to confer the highest risk. The risk
f OC among HNPCC women is of about 12%, while it may
e as high as 50% in BRCA1 mutation carrier [85]. BRCA1
utations are associated with an OC risk ranging from 28%
o 44%, compared to 1.6% in the general population. The
reast Cancer Linkage Consortium has established a lower
umulative risk of OC in families whose members are car-
iers of mutations in BRCA2, that is of 0.4% under the age
f 50 and 27% at the age of 70. Furthermore, the mean age
t diagnosis of OC in MMR genes or BRCA1 mutation car-
iers is younger than that of patients with sporadic OC (45
nd 60 years, respectively), whereas most of the OCs asso-
iated with BRCA2 mutations are diagnosed after the age of
0 [25].
Moreover, mutations in the BRCA genes confer an
ncreased risk of OC in women already affected by breast
arcinoma, which is apparently 10 times as high as that of
on-carrier women (Table 3).
. Oncogenetic counseling
Oncogenetic counseling is addressed to people with
suspected genetic predisposition to the development of
pecific neoplasms recurring within their family [86] in
rder to aware patients about their pathological genetic
ondition.
Oncogenetic counseling requires a “multidisciplinary
pproach”, involving geneticists, oncologists and psychol-
gists; each of these specialists plays a definite role within
he counseling program. Women at high risk of developing
n OC must first undergo the analysis of their family history,
heir genealogical tree must be constructed and their personal
isk must be evaluated [87] (Fig. 5).
.1. Risk evaluation
Risk calculation assesses the probability that the subject
ill develop the disease and also the woman’s personal vul-
erability. In this latter context, the psychologist is essential.
ncogenetic counseling and genetic testing can cause a seri-
us psychological stress related to the results and to the
ubsequent life changes, the loss of privacy and the possi-
le alteration of family dynamics. For these reasons, in the
ast few years, the importance of psychological support for
34 A. Russo et al. / Critical Reviews in Oncology/Hematology 69 (2009) 28–44
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ancer; OC: ovarian cancer; TPU: transvaginal pelvic ultrasound; yr: year. 1
hole family during and after the counseling has been fully
ecognized [88,89].
Nowadays, risk evaluation regarding OC patients is per-
ormed with the use of specific mathematical models, such
s BRCAPro, the Couch and Myriad I models.
The risk calculation with BRCAPro-Software result is
xpressed as a percentage value: subjects with a result of
ore than 10% are considered at high risk of being carriers of
germline mutation and will therefore undergo genetic test-
ng. This includes the molecular analysis of the susceptibility
enes. BrcaPro is a computer based Bayesian probability
odel that uses first and second-degree family history of
reast and/or ovarian cancers to determine the probability
hat a BRCA1 or BRCA2 gene mutation accounts for these
ancers.
Another model used (Myriad) allows to estimate the prob-
bility of being a BRCA mutation carrier by adopting a
t
t
o
fenes: breast cancer genes; MMR genes: mismatch repair genes; BC: breast
n, breast, colon, endometrial, pancreatic and biliary tract tumors.
able of mutations prevalence available on the Myriad web
ite.
On the contrary the BRCAPro system uses data from
ublished studies of prevalence, penetrance and mutation
requency.
The Couch model requires data from at least four fam-
ly members with BC/OC and predicts the risk of BRCA1
utation only. Moreover it does not fit to families with OC
ite-specific.
The Myriad system instead may be used in affected
ndividuals with no family history or in patients with OC
ite-specific.
It is important to underline here that every model sys-
em has some weakness and that it is the clinical experience
hat lead to the choice of the most appropriate model
r combination of models to the needs of a specific
amily [90–94].
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.2. Pedigree analysis and eligibility criteria
The reconstruction of the patient’s family history is a cor-
erstone of the genetic counseling process, since a clear
nderstanding of the genealogical tree can enhance correct
iagnosis, can allow a more accurate outcome prediction
o providing better indications about the following disease
anagement.
The reconstruction of the genealogical tree requires the
ollection of the clinico-pathological data regarding each
ember of the family, going back for at least three gener-
tions from the “proband”.
Furthermore, both paternal and maternal family history
hould be included, since most of the genes involved in the
isk of developing an ovarian tumor derive equally from the
other and the father.
Since a hereditary OC is identified by means of a care-
ul analysis of the family history, the informations leading
o the reconstruction of the pedigree must be extremely
ccurate; informations provided by the patient should be
ouble-checked by means of the evaluation of pathological
eports, death certificates or cancer registers.
As soon as the geneticist has explained that there is a pos-
ible genetic disorder within the family, the proband must
ecide whether or not to undergo genetic testing. After being
nformed about advantages and disadvantages of the proce-
ure, the patient is free to decide and to sign the informed
onsent [95].
Analyzing the family history, the geneticist will decide
hich of the main hereditary ovarian tumor syndromes is
resent in the proband’s family.
HNPCC families are generally identified by the analy-
is of a family history of colon carcinoma rather than OC
65]. These families mainly respond to the Amsterdam cri-
eria, which exclude familial adenomatous polyposis, taking
nto account cancer of the colon and related tumors in three
rst-degree relatives or else in two successive generations,
f which at least one before the age of 50. In certain fam-
lies, especially when they are not very large, the Bethesda
riteria are used; these include the Amsterdam criteria, but
lso probands affected by carcinoma of the colon diagnosed
efore the age of 60 and second-degree relatives who have
ad Lynch syndrome correlated tumors [78,80].
Families with an hereditary syndrome of site-specific OC
re recognizable by the large number of OC diagnosed before
he age of 50 among the women of the same family, whereas
BOC families present members affected by early-onset
reast cancer and OC and members with both malignancies,
ale breast carcinoma and with two or more first-degree rel-
tives with both breast and OCs diagnosed before the age of
0 [1].
The following criteria identify women at high risk for OC
ho should undergo genetic testing, taking into account the
rst grade relatives:
 two or more women with OC at any age;
t
t
p
mogy/Hematology 69 (2009) 28–44 35
 one member with OC at any age and with breast cancer
under the age of 50;
 one member with OC at any age and two relatives with
breast cancer diagnosed before the age of 60;
 one member affected who is a carrier of mutations in
genes predisposing to OC;
 three members of the family with cancer of the colon,
with at least one of them diagnosed before the age of 50
and one case of OC.
imitations in these eligibility criteria could exclude fairly
mall families or families with a large number of male mem-
ers, since they can transmit germline mutations without
anifesting related tumors. In any case, these criteria are
he only available instruments which permit the geneticist to
dentify families at high risk for developing OC [65].
.3. Genetic testing for BRCA or MMR genes
The result of the genetic testing for the identification of
erminal mutations is only able to indicate the probability, but
ot the certainty, that a cancer will develop; not in all individ-
als with a positive test for BRCA or MMR gene mutations
alignancies will occur. The genetic testing for BRCA1/2
enes provides automatic sequencing of all codifying exons
nd of the exon–intron boundaries; recent techniques allow
o detect also wide insertions and deletions involving one or
ore whole exons [96].
In HNPCC families fulfilling the Amsterdam criteria, it
s possible to directly sequencing of susceptibility genes
rom the peripheral blood of the affected patient, whereas
n families that correspond to the Bethesda criteria it could
e carried on a pre-screening analysis regarding MSI. How-
ver, in the case of a strong family history of colon cancer
nd OC, it is still useful to carry on mutational analysis
ecause HNPCC families selected with the Bethesda crite-
ia could present fewer cases of colon cancer available for
SI analysis than other types of correlated tumors, such
s OC [79].
If a particular mutation is identified in an individual
ho has been diagnosed with cancer, counseling is there-
ore advised for the other healthy family members who
ill provide written informed consent. Pre-test counseling
equires that all the individuals involved in genetic testing are
nformed about the potential advantages and disadvantages of
ancer early detection and prevention strategies, after which
hey can decide whether or not to give their consent and will
e prepared to receive the result [95,97].
.4. Disclosure of gene test results
The post-test counseling concerns the communication of
he result of the genetic test and provides another opportunity
o meet the at risk family member. This phase is necessary for
atients’ deeper understanding and/or revision of the infor-
ation they received [95].
3 Oncology/Hematology 69 (2009) 28–44
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Table 4
Histopathological features of BRCA mutation carriers
Histopathological type BRCA1 mutation,
carriers no. (%) [1–6]
BRCA2 mutation,
carriers no. (%) [2,4]
Serous 296 (55) 43 (53)
Mucinous 12 (2) 3 (4)
Endometrioid 128 (24) 22 (27)
Clear cell 54 (10) 6 (7)
Undifferentiated 13 (2) –
Other 40 (7) 7 (9)
Total 543 (100) 81 (100)
1. Berchuck A, et al. Clin Cancer Res 1998;4(10):2433–7.
2. Lakhani SR, et al. Clin Cancer Res 2004;10(7):2473–81.
3. Piver MS. Gynecol Oncol 2002;85(1):9–17.
4. Risch HA, et al. Am J Hum Genet 2001;68(3):700–10.
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The genetic test may give a positive, negative or non-
nformative result.
A result is defined as positive when a deleterious mutation
n the susceptibility genes is detected in the proband. They are
onsidered as deleterious those mutations, such as frameshift
utations due to insertions or deletions, which determine the
ormation of a truncated protein. A positive result of genetic
esting implies the research for the same mutation in all the
embers of the family and the planning of surveillance pro-
ram. Testing for a known familial mutation is easier and
heaper than full gene sequencing.
A negative result indicates that no deleterious mutations
ave been identified. If a genetic mutation has been found
reviously within the family, and the patient does not present
t, the result is considered a “true negative”, meaning that the
atient did not inherit the known familial mutation. On the
ther hand, when a negative result is obtained in a patient with
strong family history without an already known mutation,
he negative result cannot exclude the possible presence of
ther unknown germline mutations [97].
A non-informative result means that there has been the
dentification of an “unknown variant”, that is a genetic alter-
tion of unknown biological significance. This group is made
p of the missense mutations or mutations found in non-
odifying regions of the gene. Biochemical/functional assays
re required to determine the clinical significance of these
ariants [98].
Nevertheless, the genetic counseling program does not
nd with the communication of the result to the patient; the
enetic consultant should always be at the patient’s disposal
n order to answer any further questions that might occur after
isclosure counseling.
. Clinical and histopathological relationships and
rognosis
The histopathological features of OCs associated with
ermline BRCA mutations have not yet been clarified.
Since BRCA1 germline mutations are found four times
ore often than BRCA2 mutations in patients with hereditary
C, most publications investigating the correlations between
linical behavior and histopathological features in familial
C include only BRCA1 mutation carriers (Table 4).
Historically, serous carcinoma is the most common histo-
ype occurring in patients with BRCA1 mutations accounting
or more than 90% of all cases, while it is found in about
0% of sporadic OCs [99]. Nevertheless, more recent studies
eported that serous carcinomas are less frequent and BRCA
utation-associated carcinomas have pathological features
imilar to those of sporadic cancers (Table 4).
Mucinous tumors are uncommon in BRCA1 mutationarriers; it may be that mutations in BRCA1 gene are less
nvolved in the development of this OC histological type
100]. Even though only occasionally described, invasive and
orderline mucinous carcinomas have also been observed in
b
O
m
h. Rubin SC, et al. N Engl J Med 1996;335(19):1413–6.
. Stratton JF, et al. N Engl J Med 1997;336(16):1125–30.
RCA1 mutation carriers [101,102]. Other histopathological
ypes such as endometrioid and clear-cell carcinomas show
lmost the same or a slightly lower frequency in BRCA1
utation carriers versus sporadic cases. Transitional-cell and
quamous carcinomas, sarcomas and dysgerminomas are
airly rare.
OCs associated with BRCA1 and BRCA2 germline muta-
ions are high grade, present a larger solid component and
re diagnosed at a more advanced stage compared to spo-
adic ovarian tumors. In addition, they overexpress p53, while
ER2 expression is similar to that found in sporadic [101].
Similar morphological and immunophenotype patterns
ave been found in BRCA1 and 2 related OCs and in
poradic ones, whereas BRCA1/2 associated breast cancer
xpresses different features when compared to the sporadic
orm.
High grade and overexpression of p53, usually associated
ith familial OC, are generally recognized as unfavorable
rognostic factors. However one study has reported a better
rognosis among BRCA1 mutation carriers with advanced
Cs compared with a series of sporadic cases at the same
tage and a survival rate of 77 months versus 29 months,
espectively [103]. A better clinical outcome of BRCA-
ssociated cancers has also been confirmed by a national
esearch program conducted in Israel [104] and in a Japanese
tudy in patients treated with cisplatin [105]. Nevertheless,
wo further studies have found no differences in survival rate
etween patients with hereditary OC and those affected by
poradic ovarian tumors [106,107].
It has been hypothesized that OCs associated with BRCA
utations might achieve longer overall survival and disease-
ree interval after chemotherapy because of the higher
ensibility of BRCA-deficient neoplastic cells to some cyto-
oxic agents. In fact, BRCA proteins are implicated in the
echanisms of recognition and repair of DNA double-strand
reaks produced by agents such as platinum compounds.
n the other hand resistance of BRCA-associated tumors to
itotic-spindle drugs, such as taxanes and vinka alkaloids,
as been reported in model systems [108].
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The main difference between BRCA1 and 2 mutation
arriers is that the latter implicate a lower risk for tumor
evelopment, which in any case evolves later on in life.
The clinical and histopathological features of HNPCC-
inked endometrial and OCs are similar to those observed in
he most part of sporadic cases, even if they occur at an earlier
ge. These cancers are usually well differentiated, identified
t an early stage and often synchronous [66,109].
. Strategies for the primary care clinician
.1. Gynecologic screening in high-risk groups
The main goal of screening is to identify OC at an earlier
nd more curable stage. A screening program is now con-
idered conventionally acceptable if it allows to detect an
arly OC case every ten screening tests performed. Since OC
s rare in the general population, a specificity of 99.6% is
equired. In a high-risk group, such as carriers of mutations
n the BRCA1 and BRCA2 genes, 90% specificity is enough
o maintain the positive predictive value (PPV) above 10%
110].
.1.1. Pelvic examination
In the general population, this procedure has neither the
pecificity nor the sensitivity required for the efficient detec-
ion of an OC. Few data are available on its clinical usefulness
n high-risk women. A sensitivity of 40%, a specificity of
8% and a PPV of 21% has been achieved using a pelvic
xamination only [111].
.1.2. Colpocytological examination
PAP test may occasionally detect malignant cells exfoli-
ting from the ovaries, but it cannot be considered a practical
creening method for OC, since it presents a sensitivity of no
ore than 10–30% [112].
.1.3. Serum CA125
There is limited evidence to establish whether routine
creening with serum CA125 levels for the high-risk popula-
ion would result in a decrease in mortality from OC. A study
egarding 180 high-risk women reported a CA125 increase
n four out of eight ovarian epithelial carcinomas, but above
ll at an advanced stage (25% at stages I–II vs. 75% at stage
I) [113].
Bourne et al. conducted a large study on 1502 women
ith familial history of OC. They found that the CA125
ssay could improve the PPV of transvaginal pelvic ultra-
ound (TPU) from 12.7% to 42.9%, with a detrimental effect
n the sensitivity which was reduced from 100% to 43% [85].
In another study on women at high risk for hereditary
arcinoma of the breast/ovary or hereditary non-polyposis
olorectal cancer (HNPCC), this marker proved to be elevated
n 11% of the cases; during the premenopausal period rising
alues of CA125 were associated with benign pelvic diseases,
m
p
yogy/Hematology 69 (2009) 28–44 37
uch as endometriosis, adenomyosis and myomas, whereas
uring the menopause no suspect in-depth ultrasound images
ere observed [114].
.1.4. Transvaginal pelvic ultrasound (TPU)
TPU is superior to transabdominal ultrasound for the pre-
perative diagnosis of adnexal masses [115]. Both these
echniques are less specific when used in premenopausal
omen compared to those in the postmenopause due to the
varian changes occurring during the menstrual cycle. The
ositive and negative predictive values of TPU in women with
amilial history for OC are higher than the corresponding val-
es in the general population and can be further improved by
he addition of Doppler color techniques, at least in post-
enopausal women [116,117]. Two studies by Bourne et al.,
sing these tools, reported a sensitivity of 100% and a speci-
city of 97% of TPU after screening 776 women with at
east one close relative who had developed the disease and
n abnormality rate of TPU of 3.8%, that is, 61 out of 1601
omen screened, six of whom had primary OC detected at
urgery [118,119]. In another paper, all the five OCs found
n a group of 180 high-risk women had been correctly diag-
osed by TPU, but one only was at stage I, while the other
our were at stage IV [113].
.1.5. Combined screening tests
In the general population, the sensitivity of a screening
rogram based on a CA125 assay and TPU is of about
0–100%, but its predictive value is extremely low. If only
he CA125 value is considered, from 0.1 to 0.6% of healthy
omen will undergo a useless surgical procedure, and the rate
urther increases to 4.4% when TPU is used alone. A random-
zed clinical study reported that only 6 out of 10000 women
creened with sequential CA125 antigen and ultrasonography
ad a correctly diagnosed OC, half of which curable, while
4 underwent unnecessary surgery [120]. The same study
uggested that the combination of the two methods might pro-
uce an earlier diagnosis of ovarian neoplasms, which might
esult in both a downstaging of cancer and an improved sur-
ival rate. At the same time, it is clear that there are consistent
roblems and costs that must be considered when conceiv-
ng a screening program for such a rare disease. The situation
ight be different with regard to high-risk patients with muta-
ions in the genes BRCA1 and BRCA2, for whom the higher
ncidence of the disease might have a significant effect on the
ost/benefit ratio of the screening program. Moreover most
Cs that occur in women at high genetic risk are high-grade
erous cancers and these are infrequently screen-detected at
n early stage. Hogg and Friedlander reviewed 12 studies
eporting on more than 6000 high-risk screened women: of
he 38 OCs diagnosed in women at increased risk, 24 (63%)
ere stage IIC or higher [121].
The National Comprehensive Cancer Network recom-
ends that women with BRCA1 or BRCA2 mutations
articipate in intensive surveillance programs with twice-
early concurrent transvaginal ultrasound and serum CA125
3 Oncol
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http://www.nccn.org/professionals/physician gls/PDF/gen-
tics screening.pdf).
.2. Oral contraceptives
Chemoprevention is a primary prevention strategy that
ims to reduce hereditary cancer risk with drugs: oral con-
raceptives have been extensively evaluated in ovarian cancer
revention. In the population at large, the use of oral contra-
eptives is associated with a risk reduction of developing OC
anging from 40 to 50%, which increases during the period
f their use and persists for 10–15 years after their suspen-
ion [122,123]. The same effect has been observed in women
ith familial positivity for OC [124] and between BRCA1
nd BRCA2 gene mutation carriers [125]. Nevertheless, a
etrospective study on a large cohort of patients with OC sug-
ested that the protective effect did not involve the carriers
f BRCA1 mutations [126]. Furthermore, caution is required
efore oral contraceptive use can be routinely recommended
ince a higher rate of breast carcinoma has been reported
n BRCA1/2 mutation carriers who had taken oral contra-
eptives for at least 48 months (OR 7.8; p = 0.004) [127].
case–control study by Narod et al. showed an increased
isk of early-onset breast cancer, among BRCA1 mutation
arriers, in women who first used oral contraceptives before
975, who used them before age 30, or who used them for 5
r more years. Oral contraceptives did not appear to be asso-
iated with risk of breast cancer in BRCA2 mutation carriers
128]. These limited data suggest that the administration of
n oral contraceptive should not be considered as an option
or reducing the risk of OC in BRCA1/2 mutation carriers
23,129].
More recently, McLaughlin et al. published a case–control
tudy on 3223 women with BRCA mutations. The authors
eported that oral contraceptive use lead to a highly significant
eduction in ovarian cancer risk (BRCA1 odds ratio = 0.56,
RCA2 odds ratio = 0.39) in both univariate and multivariate
nalyses. The maximum protective effect was seen with 3–5
ears of oral contraceptive use [130].
.3. Prophylactic surgery
.3.1. Prophylactic salpingo-oophorectomy (PSO)
Women with ascertained BRCA1 and BRCA2 muta-
ions should be counseled that, at the present time,
rophylactic salpingo-oophorectomy is considered the most
ppropriate option to prevent OC and that it is sug-
ested after the 35th year of age or after childbearing is
ompleted (Fig. 5).
There is general agreement regarding the fact that
rotection is incomplete, since primary peritoneal carci-
oma indistinguishable from primary OC could develop in
.8–10.7% women with a history of familial OC who have
ndergone PSO, probably due to the common embryonic ori-
in of the peritoneum and the ovaric epithelium [131–133].
owever, thorough histological examination of prophylacti-
9
B
uogy/Hematology 69 (2009) 28–44
ally removed ovaries could detect foci of malignant tumors
hich were overlooked at the initial examination and were
ot be detected on ultrasonograms [134,135]; several of the
eritoneal carcinomas found in such cases might therefore
e metastases of OCs which were not diagnosed at the first
urgical intervention.
Moreover, the risk/benefit ratio of PSO should take
ccount of the potential morbidity and mortality of the sur-
ical procedure [136], of the cardiovascular risks [137], of
he possibility of osteoporosis developing [138] and of risks
inked to long-term hormone-replacement therapy (HRT)
139].
In 1995, the U.S. National Institute of Health (NIH), after
eviewing the available literature on the efficiency of PSO
s demonstrated by the follow-up of high-risk women who
ad not received genetic counseling, concluded that mutation
arriers should undergo PSO ideally after the age of 35 or
pon completion of child bearing [140].
The Cancer Genetic Studies Consortium concluded
dversely that evidence was insufficient to suggest or advise
gainst prophylactic surgery as a measure for reducing OC
isk [141].
After the publication of these recommendations, several
tudies evaluated the impact of prophylactic mastectomy
nd oophorectomy on the risk for breast and gynecological
ancers in BRCA mutation carriers [142–144]. In the most
ecent of these (Van Roosmalen et al.), PSO performed at
he age of 30 brought about an increase of expected sur-
ival rate of 5.3–9.5 years depending on the penetrance
f the gene; furthermore, a protective effect against breast
arcinoma was found when bilateral prophylactic oophorec-
omy was performed during the premenopause and this
ad also been confirmed in mutation carriers of the BRCA
enes [145].
More recently, four case–control studies have been
ublished concerning BRCA1/2 mutation carriers who
nderwent either prophylactic oophorectomy or clinico-
nstrumental follow-up [146–149] (Table 5).
In the first retrospective study (Rebbeck et al.), con-
ucted on 551 BRCA1 and BRCA2 mutation carriers,
59 women underwent oophorectomy and 292 clinico-
nstrumental follow-up for an average of 8 years. At the time
f surgery, six women (2.3%) received a diagnosis of stage I
varian neoplasms, while two cases of papillary serous peri-
oneal carcinoma (0.2%) were observed respectively 4 and
years after surgery. Among the follow-up group, 58 neo-
lasms (19.9%) were detected. Excluding those cases found
t the time of the procedure, PSO reduced the risk of celomic
pithelial cancer by 96% (IC 95% 0.01–0.16). Furthermore,
he oophorectomy proved to reduce the risk of breast car-
inoma by 47% compared to controls among women who
ad not undergone prophylactic bilateral mastectomy too (IC
5% 0.29–0.77).
Kauff et al. performed a prospective study on 170
RCA1 and BRCA2 mutation carriers, 98 of whom
nderwent prophylactic surgery and the rest were fol-
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Table 5
Case–control studies in BRCA1/2 mutation carriers undergoing PSO
Study Year No. of patients No. of PSO Gynecologic cancer at
time of surgery
Gynecologic cancer
RR (%)
Breast cancer
RR (%)
Kauff et al. [134] 2002 170 98 Two stage I ovarian 85 68One stage I fallopian tube
Rebbeck et al. [135] 2002 551 259 Six stage I ovarian 96 47
Scheuer et al. [136] 2002 251 90 One stage I ovarian 63One stage I fallopian tube
Finch et al. [137] 2006 1828 1045
Seven ovarian
80Three fallopian tube
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wSO: prophylactic salpingo-oophorectomy; RR: risk reduction.
owed with surveillance alone. During the 24.2 follow-up
onths, in the first group three breast carcinomas and one
eritoneal celomic carcinoma were found, while in the
ollow-up group, eight breast carcinomas, four OCs and
ne carcinoma of the peritoneal celomic epithelium were
etected. The hazard ratio for subsequent BRCA-related
reast and gynecologic cancer combined in the PSO group
as 0.25 (IC 95% 0.08–0.74).
The third study (Scheuer et al.) was a prospective evalua-
ion in a group of 251 mutation carriers of the genes BRCA1
nd BRCA2. Among the 90 women who underwent PSO, one
tage IC OC and one stage IA fallopian tube neoplasm were
ound at the time of surgery, while among the women who
hose follow-up one peritoneal carcinoma and three OCs at
tages I and II were detected during a median follow-up of
4.8 months.
In the largest prospective study on BRCA1 and BRCA2
utation carriers who had undergone PSO, a 80% risk reduc-
ion was calculated including ovarian, fallopian tube and
eritoneal cancers. The cumulative incidence of peritoneal
ancer in the 20 years following oophorectomy was esti-
ated to be 4.3% [149]. It was retrospectively ascertained
hat oophorectomy is also an effective means of reducing the
isk of breast cancer in BRCA1 mutations carriers [150].
Overall, these data confirm the efficacy of PSO in reducing
he risk of carcinoma of the peritoneal celomic epithelium
nd the possibility of removing stage I ovarian neoplasms
hich might have overlooked during the clinico-instrumental
xaminations. This latter fact highlights the importance of
erforming a detailed histopathological evaluation of the
xcised tissues in order to detect possible microscopic ovarian
nd fallopian tube cancers.
As a matter of fact, prophylactic surgery is more effec-
ive in decreasing ovarian cancer mortality compared to close
urveillance and chemoprevention. However any beneficial
ntervention in cancer risk reduction should be balanced
gainst concerns about quality of life and adverse effects.With regard to patient acceptance of the procedure, BRCA
utation carriers of American, Canadian and European
ationality tend to accept PSO more readily that prophylac-
ic mastectomy (50% vs. 8–28%) [151,152]. Furthermore,
a
1
v
[One malignant cytology
ost of the published studies reported greater patient satis-
action and improvement in the quality of life for women who
hose prophylactic surgery compared to those who preferred
linico-instrumental follow-up.
Menopausal symptoms are common after PSO. Most
RCA mutation carriers decide to accept HRT after pro-
hylactic adnexectomy [153–155]. Although HRT might
ncrease the incidence of breast cancer, a case/control study
eemed not to confirm this hypothesis in high-risk women.
n fact, bilateral PSO was associated with a reduced breast
ancer risk in women who carry a BRCA1 mutation (RR
.53 after 5 years and RR 0.33 after 10 years), even in HRT
sers [145,156]. Nevertheless, premature surgical menopause
learly increases osteoporosis and cardiovascular disease risk
137] that should be properly assessed and managed in each
oman who had undergone PSO.
The elective laparoscopic oophorectomy is preferable
ompared to laparotomic approach, since it involves a com-
lication rate of 9%, of which only 1–2% is serious [157].
Since the fallopian tubes might represent an elective site
f malignancy in BRCA mutation carriers, contemporary
ysterectomy is often recommended in order to remove the
sthmic portion of the salpinges in the cornua of the uterus,
lthough the real incidence in this site is unknown and the
arge majority of fallopian tube cancers originate in the distal
r middle portion [158].
.3.2. Tubal ligation
A prospective study associated this technique to a reduc-
ion of 33% of OC risk in the general population [159].
nother case–control study concerning women with BRCA1
nd BRCA2 mutations also reported a significant reduction
f the risk (OR 0.39) in those undergoing tubal ligation [160].
.3.3. PSO during hysterectomy
It has been calculated that in the general population,
omen older than 40 who undergo hysterectomy, 400 PSO
re required in order to prevent one case of OC. The resulting
0% reduction of the incidence of OC would lead to the pre-
ention of 2300 new cases a year in the United States alone
161]. In patients undergoing laparoscopic hysterectomy for
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ther indications, prophylactic oophorectomy is performed
ore often than in those where the transvaginal access is
sed [162].
Since the benefit is proportional to the incidence of the
umor, the removal of the ovaries during hysterectomy in a
roup of high-risk women would result in a higher prevention
ate of OC [136].
Furthermore, with regard to the risks of an early
enopause resulting from oophorectomy, it should be consid-
red that within 2 years since hysterectomy performed during
he premenopause, 30% of the women presents symptoms of
strogen deficit and a reduction of the bone mass even when
he ovaries have been preserved [163].
.3.4. Prophylactic hysterectomy
Simple hysterectomy is associated with a reduction of the
isk of OC in the general population [159]. Women carriers
f genetic mutations linked to the HNPCC syndrome should
e informed about possible prevention strategies. Among
NPCC families, recommendations for screening and risk
educing surgery are established for colorectal cancer but
ot for endometrial and ovarian malignancies. Women who
ompleted child-bearing, especially if undergo surgery for
olorectal carcinoma, should be counseled about prophylac-
ic hysterectomy and adnexectomy, so as to reduce the risk
f the occurrence of gynecological malignancies [164].
. Practice points
Major risk factor for the development of OC is a strong
familial history.
Three main familial syndromes are reported: HOC (heredi-
tary ovarian cancer), HBOC (hereditary breast and ovarian
cancer), HNPCC (hereditary non-polyposis colorectal can-
cer or Lynch II syndrome); the first is actually considered
a variant of HBOC.
HOC and HBOC are linked to mutation in BRCA1 and
BRCA2 genes.
HNPCC is associated to mutation in MMR genes.
Patients with strong family history for OC should be
referred for genetic counseling and potential genetic test-
ing.
Ovarian cancer associated with germline BRCA mutations
are mostly advanced stage at diagnosis and high-grade
serous carcinomas.
Recommendations for OC surveillance in women having a
strong family history or in BRCA mutation carriers include
TPU with color Doppler and serum CA125 every 6 months.
BRCA mutation carriers should undergo prophylactic
salpingo-oophorectomy after the 35th year of age or after
childbearing is completed, but it does not protect against
primary peritoneal cancer.
Hysterosalpingo-oophorectomy should be considered in
HNPCC women who undergo surgery for colorectal carci-
noma.ogy/Hematology 69 (2009) 28–44
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